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SUMMARY — Tardive dyskinesia (TI>), a serious complications of neuroleptic chronic use, 
has no effective therapy yet. We performed an experiment to study the action on TD, of the 
calcium channel blockers (CCB) drugs, verapamil and flunarizine. We obtained the TD model 
in rats, administering haloperidol for a 21-day period. After this, the stereotyped movement 
induced by apomorphyne was rated. The CCB drugs were administered in acute (in the 
28th. day) and chronic (for 8 days, after the 25th day) experiments. Acutely, verapamil 
increased the stereotyped behaviour, and promoted a reduction of it in the chronic experiment. 
The results suggest that CCB drugs should be tested in clinical trials of TD. 
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Estudo da ação de dois bloqueadores de canais de calcio sobre modelo experimental de discinesia 
tardia em ratos 
RESUMO — A discinesia tardia (DT) é complicação decorrente do uso prolongado de neuro-
lépticos. Até o presente, nenhum tratamento provou ser eficaz na DT. Evidências indiretas 
apontam para a ação de drogas bloqueadoras de canais de cálcio (BCC) em algumas vias neu-
rais. A ação de duas dessas drogas, verapamil e flunarizina, foi testada em modelo expe-
rimental de DT em rato, neste estudo. O haloperidol foi administrado por 21 dias e indução 
de movimentos estereotipados era obtida no 24<? dia, com a injeção de apomorfina. As drogas 
BCC foram administradas por uma vez no 28? dia (experimento agudo) e por 8 dias, após o 
25* dia (experimento crônico). A flunarizina não induziu modificação no padrão de estereo-
tipia dos animais, mas o verapamil levou a aumento no experimento agudo e a diminuição 
no experimento crônico. Estes achados indicam que as drogas BCC podem ter alguma ação 
sobre a DT e que ensaios clínicos devem ser feitos para se comprovar se tal ação ocorre no 
homem. 
PALAVRAS-CHAVE: discinesia tardia, drogas bloqueadoras de canais de cálcio, neuro-
lépticos. 
Tardive dyskinesia (TD), a complication of neuroleptic prolonged use, is 
due to a blockade of striatal postsynaptic dopaminergic (DA) receptors. A 
chemical denervation occurs and is followed by hypersensitivity of DA receptors. 
This can be indirectly proven by apomorphine or amphetamine DA agonists acting 
on postsynaptic receptors and in neurotransmitters release, respectively. Beha-
vioural studies show that an increase in striatal dopaminergic action produces 
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stereotyped movements in rats 15,16,23. i n spite of all therapeutic trials, no signi­
ficant improve has been observed in TD. Although, persistent researchers have 
been trying to find efficacious alternatives i>9>io. 
Recent studies have demonstrated side effects of calcium channel blockers 
(GCB) upon the CNS. Acathysia, depression, parkinsonism and dyskinesia, all se­
condary to flunarizine chronic use 7, is, 19,20 as well as dysgeusia and dysosmia1? 
induced by nifedipine may be evidences that these drugs act on neurotransmission. 
The influence of such drugs on DA system (more precisely, the nigrostriatal 
system), brought us to set up a behavioural study by means of an experimental 
model of TD in rats, making use of verapamil and flunarizine, pharmacologically 
distinct calcium channel blockers 13,25. 
MATERIAL AND METHODS 
Animals — Male Wistar rats aged between 3 and 4 months were used, and kept in cages 
in 5-animal groups in a bioterium under (lighting and temperature controlled conditions. 
Drugs — Solutions of 5 mg/ml haloperidol, 2 mg/ml apomorphine, 2 mg/ml verapamil, 
prepared with distilled water, and a flunarizine suspension prepared with 2% Tween (v/v). 
The drugs were administered intraperitoneally (i.p.) in a volume of 1 ml/kg. 
Stereotyped behaviour — The rats underwent a 21-day treatment with haloperidol, being 
kept in 5-animal cages. Apomorphine was given on the 24th day of the experiment, for the 
stereotyped movement testing. In the acute protocols the test was carried out on ithe 28th 
day, and he calcium channel blocker or (a control solution was given 20 minutes before apo­
morphine. Chronic protocols were carried out with apomorphine exclusive administration on 
the day of testing. In the provocative test, as well as in the experimental test, the animals 
were placed in individual cages for the grading of duration and intensity of stereotyped 
movement. Then, each animal was observed every 5 minutes for 30 seconds, according to a 
stereotyped grading scale, adopted for use at the Department of Psychobiology, Escola Pau-
lista de Medicina (Table 1). The experiment was deemed terminated whenever the animal 
onde again presented with normal exploratory reactions, establishing grooming as a criterion 
for finishing the test. 
Technique: 
Acute testing — Eighty rats were treated for 21 days with haloperidol 5 mg/kg i.p., and 
were divided into 8 groups with 10 (animals each. On the 24th day of the experiment apo­
morphine was administered i.p., 2 mg/kg, as a provocative test for stereotyped movements. 
On the 28th day, an experimental test with calcium channel blockers was set up. 
Experiments with verapamil: verapamil was administered i.p. in 2, 4 and 8 mg/kg doses, as 
well as saline solution 0.9% as 1a control. After 20 minutes, apomorphine 2 mg/kg was given 
i.p. Stereotyped behaviour was evaluated as1 described above. 
Experiments with flunarizine: flunarizine was administered i.p. in 1.5, and 6 mg/kg doses, 
as well as a Tween 2% suspension as a control. After 20 minutes, apomorphine 2 mg/kg was 
given i.p. Stereotyped behaviour was evaluated as described above. 
Chronic testing I — Sixty rats were treated for 21 days with haloperidol 5 mg/kg i.p., 
and were divided into 6 groups with 10 animals each. On the 24th day of the experiment apo­
morphine was administered i.p., 2 mg/kg, as a provocative test for stereotyped movements. 
From the 25th duay on, CCB were administered. 
Experiments with verapamil: verapamil was administered i.p. from the 25th to the 32nd day, 
in 4 and 8 mg/kg doses, as well as saline solution 0.9% as a control. Apomorphine 2 mg/kg 
was administered i.p. on the 32nd day of the experiment, followed by the evaluation of stereo­
typed behaviour as already described. 
Experiments with flunarizine: flunarizine was administered i.p. from the 25th to the 31st day, 
in 3 and 6 mg/kg doses, as well as a Tween 2% suspension asi a control. Apomorphine 2 mg/kg 
was administered i.p. on the 32nd day of the experiment, followed by the evaluation of 
stereotyped behaviour as (already described. 
Chronic testing II — Sixty rats were divided into 6 groups with 10 animals each, and 
were treated for 21 days with haloperidol 5 mg/k i.p. associated to CCB. 
Experiments with verapamil: the drug was administered i.p. in 4 and 8 mg/kg doses, as well 
as saline 0.9% as> a control, in association with the neuroleptic. On the 24th day of the 
experiment an experimental test with apomorphine 2 mg/kg i.p. was carried out, followed by 
the. evaluation of stereotyped behaviour as already described. 
Experiments with flunarizine: the drug was administered i.p. in 3 and 6 mg/kg doses, as well 
as a Tween 2% suspension as a control, in association with the neuroleptic. On the 24th day 
of the experiment an experimental test with apomorphine 2 mg/kg i.p. was carried out, follow­
ed by the evaluation of stereotyped behaviour as already described. 
Statistical analysis — It was obtained through the tests of Kruskafl-Wallis and Mann-
Whitney, based on the median of grades, calculated by the medians of grades in each group, 
as well as the median of maximal grades, which arose from the highest grade of stereotyped 
movement given to each animal of the group. The significance level was 5% (p <[ 0,05). 
RESULTS 
Effect of acute administration of calcium channel blockers verapamil and flunarizine on 
stereotyped behaviour, under apomorphine induction: A tendency was observed in acute ex­
periments with verapamil to an increase in the stereotyped behaviour (H = 1 5 . 6 7 ; p < 0.01), 
as analysed through the median of grades. The same did not happen when analysis was 
performed through the median of maximal grades (H = 0.80) (Table 2). In the experiments 
with flunarizine no statistically significant deviations occurred (H =3.02, and H max=1.92). 
Effect of chronic administration of CCB verapamil and flunarizine on stereotyped behaviour, 
under apomorphine induction: 
Chronic testing I — A reduction of stereotyped movements was observed in the experiments 
conducted with chronically administered verapamil under apomorphine induction, as analysed 
through the median of grades (H =7 .12; p < 0.05) and the median of maximal grades 
(2) 
(H max=9.06; p <* 0.02) (Table 3). The experiments carried out with flunarizine showed 
(2) ^* 
nc statistically significant different behaviour (H =5.58, and H ma»=0.39). 
(2) (2) 
Chronic testing II — No statistically significant changes in stereotyped behaviour were observed 
in these experiments, with verapamil administration (H «=2.65, and H max=1.77). 
COMMENTS 
Experimental studies with animals are useful tools in the study of TD despite 
the limitation of not replicate exactly what happens to man. All models involve 
chronic neuroleptic administration that, in the end, will lead to an increase in the 
stereotyped behaviour induced by DA agonists. This behaviour can be shortly 
obtained in animals through 3-week use of neuroleptics followed by the admi­
nistration of dopaminergic agonists for some days after neuroleptic withdrawal *> 
15,16,23,28. The number and affinity of striatal DA receptors are increased in the 
experimental TD models employing rats treated with neuroleptics 3,5,14. 
CCB seem to mimick the effects of extracellular deprivation of calcium. 
Calcium ion is important in several biological processes, including cellular me­
tabolism and neurotransmission. Reactions involving calcium in the homeostasis 
take place in specific proteins that bind to the ion inhibiting or activating enzymes 
involved in different processes, some of which still obscure 24 , 2 5 . 
In our experiments we attempted to show the action of verapamil and 
flunarizine, pharmacologically distinct CCB 1 3 » 2 5, in the hypersensitization of post­
synaptic striatal DA receptors, manifested through the stereotyped behaviour of 
the animals. These substances were acutely and chronically employed by us; in 
the last case we noted their actions in association with haloperidol, and after 
hypersensitization of postsynaptic striatal receptors by the neuroleptic. 
Acute administration of verapamil, in the doses adopted in our experiments, 
do demostrate an increase in stereotyped behaviour in the animals. This could be 
resulted from a mechanism of action other than its known CCB action. It could 
still be acting synergistically with apomorphine in the DA system. In the doses 
employed by us, which are relatively low in relation to other studies, verapamil 
might be interacting with presynaptic receptors in a similar way to DA antago­
nists. It is known that low concentrations of these drugs increase the release of 
dopamine, due to the action on auto-receptors, which are calcium-dependent. DA 
agonists reduce this release, while antagonists increase it 27. 
The effects of chronically administered verapamil, after hypersensitization 
of postsynaptic DA receptors seem to be evident. The reduction of stereotyped 
behaviour in rats may suggest that this substance have cumulative properties on 
DA receptors and, in consequence, could reduce receptor hypersensitivity to the 
neurotransmitter manifested by stereotyped behaviour. This may result from the 
development of subsensitivity at the DA receptor, induced by the CCB, or even 
by another mechanism different from its action on calcium channels. 
Studies employing rabbit hypothalamus have shown an increase on norepine-
phrine release, under low concentrations of verapamil, resulting from a blockade 
to auto-receptor due to specific properties of antagonism to alpha-2 adrenocep-
tor 8. Low verapamil doses administered to a TD model in rats did not show any 
effect on stereotyped behaviour 6,21 while high doses suppressed both hyperkinesia 
and dyskinesia in these animals 6. At high concentrations, verapamil tends to inhibit 
the release of dopamine and acetylcholine in the CNS, by blocking striatal DA 
receptors 2 6 . 
Despite its inhibitory effect upon stereotyped behaviour when chronically 
used after hypersentization of postsynaptic striatal DA receptors, if verapamil 
is given along with haloperidol, it does not prevent the development of receptor 
hypersensitivity resulting from neuroleptic prolonged use. Although we did not 
observed the influence of verapamil on stereotyped behaviour in rats, other studies 
have shown different actions for this CCB. Chronic high dose use of verapamil or 
dilthiazem along with haloperidol administration for 28 days in rats, prevented 
the development of behavioural hyperactivity under apomorphine use; nevertheless, 
the same was not verified with nifedipine use 1 2 . 
Flunarizine testing did not show any influence on stereotyped behaviour in 
the animals, in the employed doses. Yet, other protocols using high acute doses 
of flunarizine and nifedine in mice showed reduced behavioural hyperactivity in 
responses to amphetamine. Consequently, one cannot state that this drug has 
no effect on TD; maybe at higher doses this can be demonstrated. 
CCB can decrease calcium utilization during the process of cellular activa-
tion. This may point to an important role for calcium in TD, since the ion is 
necessary for some metabolic processes, and for neurotransmission. 
Some investigators have shown a reduction of dyskinetic movements in 
schizophrenic patients presenting wit TD secondary to neuroleptic use, by the use 
both of verapamil2 and dilthiazem 22. This could be a demonstration of the effect 
of CCB substances upon TD. As all therapeutic trials have not so far offered any 
efficacious treatment of TD, CCB substances might prove to be a new choice to 
solve the problem. 
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